In postmenopausal women, denosumab significantly reduced bone loss.265 In experimental periodontitis models, RANKL-Fc and OPG-Fc therapies also decreased osteoclast activity and alveolar bone resorption induced by P. gingivalis infection.266 However, denosumab use is associated with adverse effects, including osteonecrosis of the jaw and atypical femoral fractures, which limit its applicability in periodontitis.267–270. Here, TNFRSF11B is linked to periodontitis.